{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:32Z","timestamp":1792008092494,"version":"4.4.0"},"reference-count":278,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40259-024-00696-9","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T15:15:06Z","timestamp":1734362106000},"page":"103-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sequelae of B-Cell Depleting Therapy: An Immunologist\u2019s Perspective"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2035-6998","authenticated-orcid":false,"given":"Mark","family":"Kacar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1535-8909","authenticated-orcid":false,"given":"Adam","family":"Al-Hakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7910-0554","authenticated-orcid":false,"given":"Sinisa","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"6","key":"696_CR1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"OC Bruton","year":"1952","unstructured":"Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722\u20138.","journal-title":"Pediatrics"},{"issue":"7","key":"696_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nri3857","volume":"15","author":"P Shen","year":"2015","unstructured":"Shen P, Fillatreau S. Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol. 2015;15(7):441\u201351.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"696_CR3","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood. 1997;90(6):2188\u201395.","journal-title":"Blood"},{"issue":"5","key":"696_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nri1838","volume":"6","author":"JCW Edwards","year":"2006","unstructured":"Edwards JCW, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol. 2006;6(5):394\u2013403.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"696_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10875-012-9755-3","volume":"33","author":"NM Chase","year":"2013","unstructured":"Chase NM, Verbsky JW, Hintermeyer MK, Waukau JK, Tomita-Mitchell A, Casper JT, et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol. 2013;33(1):30\u20139.","journal-title":"J Clin Immunol"},{"issue":"5","key":"696_CR6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.20111675","volume":"209","author":"TA Barr","year":"2012","unstructured":"Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. 2012;209(5):1001\u201310.","journal-title":"J Exp Med"},{"issue":"2","key":"696_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/acr.22921","volume":"69","author":"R Aguiar","year":"2017","unstructured":"Aguiar R, Ara\u00fajo C, Martins-Coelho G, Isenberg D. Use of rituximab in systemic lupus erythematosus: a single center experience over 14 years. Arthritis Care Res (Hoboken). 2017;69(2):257\u201362.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"1\u20132","key":"696_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","volume":"180","author":"AH Cross","year":"2006","unstructured":"Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180(1\u20132):63\u201370.","journal-title":"J Neuroimmunol"},{"issue":"8","key":"696_CR9","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","volume":"95","author":"HH Wang","year":"2015","unstructured":"Wang HH, Liu CW, Li YC, Huang YC. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95(8):928\u201332.","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"696_CR10","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, L\u00e9ger-Falandry C, Cogliatti S, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Cli. Ann Oncol. 2005;16(10):1675\u201382.","journal-title":"Ann Oncol"},{"issue":"5","key":"696_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","volume":"265","author":"EC Tallantyre","year":"2018","unstructured":"Tallantyre EC, Whittam DH, Jolles S, Paling D, Robertson CCNP, Jacob A. Secondary antibody deficiency\u202f: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018;265(5):1115\u201322.","journal-title":"J Neurol"},{"issue":"3","key":"696_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1532\/IJH97.05105","volume":"84","author":"K Fukuno","year":"2006","unstructured":"Fukuno K, Tsurumi H, Ando N, Kanemura N, Goto H, Tanabashi S, et al. Late-onset neutropenia in patients treated with rituximab for non-Hodgkin\u2019s lymphoma. Int J Hematol. 2006;84(3):242\u20137.","journal-title":"Int J Hematol"},{"issue":"2","key":"696_CR13","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.3324\/haematol.2019.220590","volume":"105","author":"TWH Flinsenberg","year":"2020","unstructured":"Flinsenberg TWH, Tromedjo CC, Hu N, Liu Y, Guo Y, Thia KYT, et al. Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. Haematologica. 2020;105(2):e76\u20139.","journal-title":"Haematologica"},{"issue":"4","key":"696_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000200004","volume":"9","author":"MR Von Essen","year":"2022","unstructured":"Von Essen MR, Hansen RH, H\u00f8jgaard C, Ammitzb\u00f8ll C, Wiendl H, Sellebjerg F. Ofatumumab modulates inflammatory T cell responses and migratory potential in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):1\u201313.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"October","key":"696_CR15","doi-asserted-by":"publisher","first-page":"S352","DOI":"10.1016\/S2152-2650(22)01487-2","volume":"22","author":"D Belada","year":"2022","unstructured":"Belada D, Kopeckova K, Burgues JMB, Stevens D, Nowakowski GS, Waldron-Lynch M, et al. ABCL-022 pharmacokinetics and pharmacodynamics in first-MIND: a phase Ib, open-label, randomized study of tafasitamab \u00b1 lenalidomide + R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22(October):S352.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"696_CR16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40263-021-00810-3","volume":"35","author":"N Seery","year":"2021","unstructured":"Seery N, Sharmin S, Li V, Nguyen AL, Meaton C, Atvars R, et al. Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: a retrospective cohort study. CNS Drugs. 2021;35(8):907\u201318.","journal-title":"CNS Drugs"},{"issue":"8","key":"696_CR17","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/1756-185X.13596","volume":"22","author":"Y Shi","year":"2019","unstructured":"Shi Y, Wu Y, Ren Y, Jiang Y, Chen Y. Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis. 2019;22(8):1361\u201370.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"696_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.20411\/pai.v6i1.435","volume":"6","author":"JM Jones","year":"2021","unstructured":"Jones JM, Faruqi AJ, Sullivan JK, Calabrese C, Calabrese LH. COVID-19 outcomes in patients undergoing B cell depletion therapy and those with humoral immunodeficiency states: a scoping review. Pathog Immun. 2021;6(1):76\u2013103.","journal-title":"Pathog Immun."},{"issue":"6","key":"696_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/ACI.0000000000000860","volume":"22","author":"M Ka\u010dar","year":"2022","unstructured":"Ka\u010dar M, Markelj G, Av\u010din T. Autoimmune and autoinflammatory manifestations in inborn errors of immunity. Curr Opin Allergy Clin Immunol. 2022;22(6):343\u201351.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"696_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1172\/JCI40231","volume":"120","author":"TW Kuijpers","year":"2010","unstructured":"Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IAM, Dolman KM, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Investig. 2010;120(1):214\u201322.","journal-title":"J Clin Investig"},{"issue":"8","key":"696_CR21","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1016\/S2665-9913(20)30033-3","volume":"2","author":"L Garcia-Montoya","year":"2020","unstructured":"Garcia-Montoya L, Villota-Eraso C, Yusof MYM, Vital EM, Emery P. Lessons for rituximab therapy in patients with rheumatoid arthritis. Lancet Rheumatol. 2020;2(8):e497-509.","journal-title":"Lancet Rheumatol."},{"issue":"4","key":"696_CR22","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.4049\/jimmunol.1600089","volume":"197","author":"E Schuh","year":"2016","unstructured":"Schuh E, Berer K, Mulazzani M, Feil K, Meinl I, Lahm H, et al. Features of human CD3+CD20+ T cells. J Immunol. 2016;197(4):1111\u20137.","journal-title":"J Immunol"},{"issue":"1","key":"696_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/brain\/awy301","volume":"142","author":"MR von Essen","year":"2019","unstructured":"von Essen MR, Ammitzb\u00f8ll C, Hansen RH, Petersen ERS, McWilliam O, Marquart HV, et al. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. Brain. 2019;142(1):120\u201332.","journal-title":"Brain"},{"issue":"2","key":"696_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000000940","volume":"8","author":"JI Fern\u00e1ndez-Velasco","year":"2021","unstructured":"Fern\u00e1ndez-Velasco JI, Kuhle J, Monreal E, Meca-Lallana V, Meca-Lallana J, Izquierdo G, et al. Effect of ocrelizumab in blood leukocytes of patients with primary progressive MS. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):1\u20139.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"1","key":"696_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13317-017-0100-y","volume":"8","author":"FH Du","year":"2017","unstructured":"Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Autoimmun Highlights. 2017;8(1):1\u201312.","journal-title":"Autoimmun Highlights."},{"issue":"6","key":"696_CR26","first-page":"676","volume":"2","author":"P Boross","year":"2012","unstructured":"Boross P, Leusen JHW. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;2(6):676\u201390.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"696_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"696_CR28","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494\u2013506.","journal-title":"Haematologica"},{"issue":"1","key":"696_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein C, Lammens A, Sch\u00e4fer W, Georges G, Schwaiger M, M\u00f6ssner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5(1):22\u201333.","journal-title":"MAbs"},{"issue":"15","key":"696_CR30","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1182\/blood-2011-12-395541","volume":"119","author":"J Honeychurch","year":"2012","unstructured":"Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012;119(15):3523\u201333.","journal-title":"Blood"},{"issue":"3","key":"696_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102466","volume":"19","author":"K Kridin","year":"2020","unstructured":"Kridin K, Ahmed AR. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. Autoimmun Rev. 2020;19(3): 102466.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"696_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjno-2020-000108","volume":"3","author":"K Smoot","year":"2021","unstructured":"Smoot K, Chen C, Stuchiner T, Lucas L, Grote L, Cohan S. Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study. BMJ Neurol Open. 2021;3(2):1\u20137.","journal-title":"BMJ Neurol Open."},{"issue":"1","key":"696_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40265-021-01650-7","volume":"82","author":"C Kang","year":"2022","unstructured":"Kang C, Blair HA. Ofatumumab: a review in relapsing forms of multiple sclerosis. Drugs. 2022;82(1):55\u201362.","journal-title":"Drugs"},{"issue":"3","key":"696_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","volume":"84","author":"AK Carlson","year":"2024","unstructured":"Carlson AK, Amin M, Cohen JA. Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability. Drugs. 2024;84(3):285\u2013304.","journal-title":"Drugs"},{"issue":"2","key":"696_CR35","first-page":"161","volume":"34","author":"MJ Leandro","year":"2020","unstructured":"Leandro MJ. Infections related to biologics: agents targeting B cells. Infect Dis Clin. 2020;34(2):161\u201378.","journal-title":"Infect Dis Clin"},{"issue":"4","key":"696_CR36","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.26028","volume":"89","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780\u20139.","journal-title":"Ann Neurol"},{"issue":"6","key":"696_CR37","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","volume":"3","author":"J Avouac","year":"2021","unstructured":"Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3(6):e419\u201326.","journal-title":"Lancet Rheumatol."},{"issue":"7","key":"696_CR38","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676\u201388.","journal-title":"N Engl J Med"},{"issue":"1","key":"696_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40620-014-0135-3","volume":"28","author":"D Geetha","year":"2015","unstructured":"Geetha D, Kallenberg C, Stone JH, Salama AD, Appel GB, Duna G, et al. Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. J Nephrol. 2015;28(1):17\u201327.","journal-title":"J Nephrol"},{"issue":"25","key":"696_CR40","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JCW Edwards","year":"2004","unstructured":"Edwards JCW, Szczepa\u0144ski L, Szechi\u0144ski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572\u201381.","journal-title":"N Engl J Med"},{"issue":"2","key":"696_CR41","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","volume":"75","author":"AJ Mohammad","year":"2016","unstructured":"Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry MJ, Amudala N, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss). Ann Rheum Dis. 2016;75(2):396\u2013401.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"696_CR42","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222\u201333.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"696_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","volume":"122","author":"JH Anolik","year":"2007","unstructured":"Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol. 2007;122(2):139\u201345.","journal-title":"Clin Immunol"},{"issue":"2","key":"696_CR44","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JCW. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(2):613\u201320.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"696_CR45","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1002\/art.22019","volume":"54","author":"P Roll","year":"2006","unstructured":"Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54(8):2377\u201386.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"696_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-017-1306-0","volume":"19","author":"J Thiel","year":"2017","unstructured":"Thiel J, Rizzi M, Engesser M, Dufner AK, Troilo A, Lorenzetti R, et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther. 2017;19(1):1\u20137.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"696_CR47","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","volume":"23","author":"LN Gordan","year":"2005","unstructured":"Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol. 2005;23(6):1096\u2013102.","journal-title":"J Clin Oncol"},{"issue":"8","key":"696_CR48","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00262-011-1168-2","volume":"61","author":"D Stroopinsky","year":"2012","unstructured":"Stroopinsky D, Katz T, Rowe JM, Melamed D, Avivi I. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother. 2012;61(8):1233\u201341.","journal-title":"Cancer Immunol Immunother"},{"key":"696_CR49","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0952-7915(98)80162-3","volume":"10","author":"MK Slifka","year":"1998","unstructured":"Slifka MK, Ahmedt R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production Mark K Slifka* and Rafi Ahmedt Addresses. Curr Opin Immunol. 1998;10:252\u20138.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"696_CR50","first-page":"91","volume":"76","author":"M Nishio","year":"2006","unstructured":"Nishio M, Endo T, Fujimoto K, Sato N, Sakai T, Obara M, et al. Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol. 2006;76(1):91\u201391.","journal-title":"Eur J Haematol"},{"issue":"2","key":"696_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1600-0609.2008.01174.x","volume":"82","author":"M Nishio","year":"2009","unstructured":"Nishio M, Endo T, Fujimoto K, Yamamoto S, Obara M, Yamaguchi K, et al. FCGR3A-158V\/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin\u2019s lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Eur J Haematol. 2009;82(2):143\u20137.","journal-title":"Eur J Haematol"},{"issue":"6","key":"696_CR52","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","volume":"36","author":"EAA Christou","year":"2017","unstructured":"Christou EAA, Giardino G, Worth A, Ladomenou F. Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab. Int Rev Immunol. 2017;36(6):352\u20139.","journal-title":"Int Rev Immunol"},{"key":"696_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60\u20135.","journal-title":"J Autoimmun"},{"issue":"2","key":"696_CR54","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","volume":"13","author":"C Casulo","year":"2013","unstructured":"Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106\u201311.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"696_CR55","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825\u201333.","journal-title":"J Clin Oncol"},{"issue":"1","key":"696_CR56","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/cancers7010305","volume":"7","author":"J Worch","year":"2015","unstructured":"Worch J, Makarova O, Burkhardt B. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers (Basel). 2015;7(1):305\u201328.","journal-title":"Cancers (Basel)."},{"issue":"9","key":"696_CR57","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/annonc\/mdl141","volume":"17","author":"F Cabanillas","year":"2006","unstructured":"Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol. 2006;17(9):1424\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"696_CR58","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12308-020-00417-5","volume":"13","author":"CM McNulty","year":"2020","unstructured":"McNulty CM, Isikwei EA, Shrestha P, Snyder MR, Kabat BF, Rabe KG, et al. Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies. J Hematop. 2020;13(4):221\u20139.","journal-title":"J Hematop"},{"issue":"1","key":"696_CR59","first-page":"14","volume":"16","author":"O Yokus","year":"2022","unstructured":"Yokus O, Jafarli K, Sametoglu F, Goze H, Serin I. Secondary immunodeficiency frequency in patients with chronic lymphocytic leukemia: the relationship with stage and treatment. Int J Hematol Oncol Stem Cell Res. 2022;16(1):14\u201321.","journal-title":"Int J Hematol Oncol Stem Cell Res."},{"issue":"9","key":"696_CR60","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF Van Vollenhoven","year":"2013","unstructured":"Van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496\u2013502.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"696_CR61","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","volume":"48","author":"G Boleto","year":"2018","unstructured":"Boleto G, Avouac J, Wipff J, Forien M, Dougados M, Roux C, et al. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study. Semin Arthritis Rheum. 2018;48(2):149\u201354.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"696_CR62","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/rheumatology\/keaa617","volume":"60","author":"G Evangelatos","year":"2021","unstructured":"Evangelatos G, Fragoulis GE, Klavdianou K, Moschopoulou M, Vassilopoulos D, Iliopoulos A. Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience. Rheumatology (United Kingdom). 2021;60(5):2375\u201382.","journal-title":"Rheumatology (United Kingdom)."},{"issue":"8","key":"696_CR63","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1093\/rheumatology\/keac716","volume":"62","author":"MA Podest\u00e0","year":"2023","unstructured":"Podest\u00e0 MA, Mescia F, Ricchiuto A, Smith R, Tedesco M, Cassia MA, et al. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study. Rheumatology. 2023;62(8):2850\u20134.","journal-title":"Rheumatology"},{"key":"696_CR64","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60\u20135. https:\/\/doi.org\/10.1016\/j.jaut.2014.11.009.","journal-title":"J Autoimmun"},{"issue":"May","key":"696_CR65","first-page":"1","volume":"12","author":"J Tieu","year":"2021","unstructured":"Tieu J, Smith RM, Gopaluni S, Kumararatne DS, McClure M, Manson A, et al. Rituximab associated hypogammaglobulinemia in autoimmune disease. Front Immunol. 2021;12(May):1\u20139.","journal-title":"Front Immunol"},{"issue":"5","key":"696_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0037626","volume":"7","author":"N Venhoff","year":"2012","unstructured":"Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D, et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS ONE. 2012;7(5):1\u20138.","journal-title":"PLoS ONE"},{"issue":"11","key":"696_CR67","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","volume":"52","author":"E Besada","year":"2013","unstructured":"Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology (United Kingdom). 2013;52(11):2041\u20137.","journal-title":"Rheumatology (United Kingdom)."},{"issue":"1","key":"696_CR68","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001115","volume":"9","author":"M Perriguey","year":"2022","unstructured":"Perriguey M, Maarouf A, Stellmann JP, Rico A, Boutiere C, Demortiere S, et al. Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with rituximab. Neurol Neuroimmunol Neuroinflamm. 2022;9(1): e1115.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"696_CR69","doi-asserted-by":"crossref","unstructured":"Salzer J, Svenningsson R, Alping P, Novakova L, Bj\u00f6rck A, Fink K, et al. Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy [Internet]. 2016. https:\/\/www.neurology.org","DOI":"10.1212\/WNL.0000000000003331"},{"issue":"5","key":"696_CR70","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/art.40032","volume":"69","author":"FB Cortazar","year":"2017","unstructured":"Cortazar FB, Pendergraft WF, Wenger J, Owens CT, Laliberte K, Niles JL. Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2017;69(5):1045\u201353.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"696_CR71","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone E, Fleischmann R, Emery P, Furst DE, Van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896\u2013908.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"696_CR72","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1182\/blood.V110.11.1288.1288","volume":"110","author":"K Filanovsky","year":"2007","unstructured":"Filanovsky K, Shvidel L, Shtalrid M, Haran M, Duek A, Berrebi A. Predictive factors to hypogammaglobulinemia and non-neutropenic infection complications after rituximab\/chemotherapy treatment. Blood. 2007;110(11):1288.","journal-title":"Blood"},{"issue":"3","key":"696_CR73","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200211","volume":"11","author":"A Langer-Gould","year":"2024","unstructured":"Langer-Gould A, Li BH, Smith JB, Xu S. Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections. Neurol Neuroimmunol Neuroinflamm. 2024;11(3): e200211.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"696_CR74","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","volume":"51","author":"I De la torre","year":"2012","unstructured":"De la torre I, Leandro MJ, Valor L, Becerra E, Edwards JCW, Cambridge G. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology. 2012;51(5):833\u201340.","journal-title":"Rheumatology"},{"issue":"2","key":"696_CR75","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jaci.2021.03.041","volume":"148","author":"R Labrosse","year":"2021","unstructured":"Labrosse R, Barmettler S, Derfalvi B, Blincoe A, Cros G, Lacombe-Barrios J, et al. Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients. J Allergy Clin Immunol. 2021;148(2):523-532.e8.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"696_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2474-15-178","volume":"15","author":"H Marco","year":"2014","unstructured":"Marco H, Smith RM, Jones RB, Guerry MJ, Catapano F, Burns S, et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord. 2014;15(1):1\u20139.","journal-title":"BMC Musculoskelet Disord"},{"issue":"11","key":"696_CR77","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/art.40937","volume":"71","author":"MY Md Yusof","year":"2019","unstructured":"Md Yusof MY, Vital EM, McElvenny DM, Hensor EMA, Das S, Dass S, et al. Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2019;71(11):1812\u201323.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"696_CR78","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.27555","volume":"62","author":"JE Gottenberg","year":"2010","unstructured":"Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625\u201332.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"696_CR79","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.25034","volume":"62","author":"CO Bingham","year":"2010","unstructured":"Bingham CO, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62(1):64\u201374.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"696_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):1\u201314.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"696_CR81","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12032-008-9049-z","volume":"25","author":"D Tesfa","year":"2008","unstructured":"Tesfa D, Gelius T, Sander B, Kimby E, Fadeel B, Palmblad J, et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol. 2008;25(4):374\u20139.","journal-title":"Med Oncol"},{"issue":"1","key":"696_CR82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/rmdopen-2014-000034","volume":"1","author":"JH Salmon","year":"2015","unstructured":"Salmon JH, Cacoub P, Combe B, Sibilia J, Pallot-Prades B, Fain O, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015;1(1):3\u20137.","journal-title":"RMD Open"},{"key":"696_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102019","volume":"41","author":"J Rigal","year":"2020","unstructured":"Rigal J, Ciron J, L\u00e9pine Z, Biotti D. Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases. Mult Scler Relat Disord. 2020;41: 102019.","journal-title":"Mult Scler Relat Disord."},{"issue":"6","key":"696_CR84","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1586\/ehm.11.62","volume":"4","author":"D Tesfa","year":"2011","unstructured":"Tesfa D, Palmblad J. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol. 2011;4(6):619\u201325.","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"696_CR85","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s10067-016-3313-y","volume":"35","author":"WE Monaco","year":"2016","unstructured":"Monaco WE, Jones JD, Rigby WFC. Rituximab associated late-onset neutropenia\u2014a rheumatology case series and review of the literature. Clin Rheumatol. 2016;35(10):2457\u201362.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"696_CR86","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/10428190500473113","volume":"47","author":"C Cattaneo","year":"2006","unstructured":"Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma. 2006;47(6):1013\u20137.","journal-title":"Leuk Lymphoma"},{"key":"696_CR87","doi-asserted-by":"crossref","unstructured":"Stamatopoulos K, Papadaki T, Pontikoglou C, Athanasiadou I, Stavroyianni N, Bux J, et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Vol. 22, Leukemia. England; 2008. p. 1446\u20139.","DOI":"10.1038\/sj.leu.2405077"},{"issue":"6","key":"696_CR88","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1046\/j.1365-2141.2003.04385.x","volume":"121","author":"K Chaiwatanatorn","year":"2003","unstructured":"Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003;121(6):913\u20138.","journal-title":"Br J Haematol"},{"issue":"2","key":"696_CR89","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.3324\/haematol.11031","volume":"92","author":"B Terrier","year":"2007","unstructured":"Terrier B, Ittah M, Tourneur L, Louache F, Soumelis V, Lavie F, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica. 2007;92(2):e20\u20133.","journal-title":"Haematologica"},{"issue":"1","key":"696_CR90","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","volume":"25","author":"T Robak","year":"2011","unstructured":"Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs. 2011;25(1):13\u201325.","journal-title":"BioDrugs"},{"issue":"7","key":"696_CR91","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00296-017-3675-8","volume":"37","author":"AI Abushouk","year":"2017","unstructured":"Abushouk AI, Ahmed H, Ismail A, Elmaraezy A, Badr AS, Gadelkarim M, et al. Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis. Rheumatol Int. 2017;37(7):1053\u201364.","journal-title":"Rheumatol Int"},{"issue":"9","key":"696_CR92","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.38037","volume":"65","author":"EF Mysler","year":"2013","unstructured":"Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368\u201379.","journal-title":"Arthritis Rheum"},{"key":"696_CR93","first-page":"689","volume":"4","author":"J Taylor","year":"2011","unstructured":"Taylor J, Schechtman J. Single-versus dual-infusion of B-cell-depleting antibody ocrelizumab in rheumatoid arthritis: results from the phase III FEATURE trial. Int J Clin Rheumatol. 2011;4:689\u201396.","journal-title":"Int J Clin Rheumatol"},{"issue":"2","key":"696_CR94","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/art.33317","volume":"64","author":"W Rigby","year":"2012","unstructured":"Rigby W, Tony HP, Oelke K, Combe B, Laster A, Von Muhlen CA, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 2012;64(2):350\u20139.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"696_CR95","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209\u201320.","journal-title":"N Engl J Med"},{"issue":"6","key":"696_CR96","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.medj.2023.05.001","volume":"4","author":"A Schuckmann","year":"2023","unstructured":"Schuckmann A, Steffen F, Zipp F, Bittner S, Pape K. Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis. Med. 2023;4(6):361-372.e3.","journal-title":"Med"},{"issue":"March","key":"696_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102279","volume":"44","author":"D Baker","year":"2020","unstructured":"Baker D, Pryce G, James LK, Marta M, Schmierer K. The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Mult Scler Relat Disord. 2020;44(March): 102279.","journal-title":"Mult Scler Relat Disord."},{"issue":"15_supplement","key":"696_CR98","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1212\/WNL.96.15_supplement.4292","volume":"96","author":"S Hauser","year":"2021","unstructured":"Hauser S, Strauli N, Raievska A, Harp C, Koendgen H, Kletzl H, et al. B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis (4292). Neurology. 2021;96(15_supplement):4292.","journal-title":"Neurology"},{"issue":"16","key":"696_CR99","doi-asserted-by":"publisher","first-page":"E1546","DOI":"10.1212\/WNL.0000000000012700","volume":"97","author":"SL Hauser","year":"2021","unstructured":"Hauser SL, Kappos L, Montalban X, Craveiro L, Chognot C, Hughes R, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021;97(16):E1546\u201359.","journal-title":"Neurology"},{"issue":"March","key":"696_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103798","volume":"62","author":"M Habek","year":"2022","unstructured":"Habek M, Piska\u010d D, Gabeli\u0107 T, Barun B, Adamec I, Krbot SM. Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab. Mult Scler Relat Disord. 2022;62(March): 103798.","journal-title":"Mult Scler Relat Disord."},{"key":"696_CR101","doi-asserted-by":"crossref","unstructured":"Derfuss T, Weber M, Hughes R, Eggebrecht J, Wang Q, Sauter A, et al. Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. In: Presented at the 35th congress of the European committee for treatment and research in multiple clinical neurophysiology. 2020;131(4):e196.","DOI":"10.1016\/j.clinph.2019.12.042"},{"key":"696_CR102","unstructured":"OCREVUS 300 mg concentrate for solution for infusion\u2014Summary of Product Characteristics (SmPC)\u2014(emc) [Internet]. [cited 2024 Apr 3]. https:\/\/www.medicines.org.uk\/emc\/product\/8898\/smpc#gref."},{"key":"696_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578066","volume":"377","author":"V Mears","year":"2023","unstructured":"Mears V, Jakubecz C, Seeco C, Woodson S, Serra A, Abboud H. Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD. J Neuroimmunol. 2023;377: 578066.","journal-title":"J Neuroimmunol"},{"key":"696_CR104","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1212\/WNL.0000000000010380","volume":"95","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020;95:1999\u20132008.","journal-title":"Neurology"},{"issue":"3","key":"696_CR105","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"409","key":"696_CR106","volume":"2020","author":"C Zanetta","year":"2019","unstructured":"Zanetta C, Robotti M, Nozzolillo A, Sangalli F, Liberatore G, Nobile-Orazio E, et al. Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature. J Neurol Sci. 2019;2020(409): 116603.","journal-title":"J Neurol Sci"},{"issue":"1","key":"696_CR107","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5299","volume":"10","author":"R Rauniyar","year":"2022","unstructured":"Rauniyar R, Rauniyar R, Agrawal A, Yadav S, Avula S. Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: a case report. Clin Case Rep. 2022;10(1): e05299.","journal-title":"Clin Case Rep."},{"issue":"1","key":"696_CR108","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1941874420936438","volume":"11","author":"J Baird-Gunning","year":"2021","unstructured":"Baird-Gunning J, Yun J, Stevenson W, Ng K. Severe delayed-onset neutropenia induced by ocrelizumab. Neurohospitalist. 2021;11(1):59\u201361.","journal-title":"Neurohospitalist."},{"issue":"1","key":"696_CR109","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/13524585231206218","volume":"30","author":"Y Beigneux","year":"2024","unstructured":"Beigneux Y, Louapre C, Bihan K, Roux T, de Paz R, Lubetzki C, et al. Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab. Mult Scler J. 2024;30(1):131\u20133.","journal-title":"Mult Scler J"},{"issue":"April","key":"696_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102155","volume":"43","author":"M Auer","year":"2020","unstructured":"Auer M, Bsteh G, Hegen H, Wurth S, Zinganell A, Berger T, et al. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab. Mult Scler Relat Disord. 2020;43(April): 102155.","journal-title":"Mult Scler Relat Disord."},{"issue":"6","key":"696_CR111","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","volume":"104","author":"JL Teeling","year":"2004","unstructured":"Teeling JL, French RR, Cragg MS, Van Den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793\u2013800.","journal-title":"Blood"},{"issue":"12","key":"696_CR112","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1634\/theoncologist.2010-0255","volume":"15","author":"I Gravanis","year":"2010","unstructured":"Gravanis I, Ersb\u00f8ll J, Skovlund E, Abadie E, Marty M, Pignatti F. The European Medicines Agency Review of Ofatumumab (Arzerra\u00ae) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the Scientific Assessment of the European Medicines Agency Committee for Medi. Oncologist. 2010;15(12):1335\u201343.","journal-title":"Oncologist"},{"issue":"3","key":"696_CR113","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40263-021-00895-w","volume":"36","author":"H Yu","year":"2022","unstructured":"Yu H, Graham G, David OJ, Kahn JM, Savelieva M, Pigeolet E, et al. Population pharmacokinetic-B cell modeling for ofatumumab in patients with relapsing multiple sclerosis. CNS Drugs. 2022;36(3):283\u2013300.","journal-title":"CNS Drugs"},{"issue":"6","key":"696_CR114","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/13524585211044479","volume":"28","author":"A Bar-Or","year":"2022","unstructured":"Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler J. 2022;28(6):910\u201324.","journal-title":"Mult Scler J"},{"issue":"September","key":"696_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103250","volume":"56","author":"J Avasarala","year":"2021","unstructured":"Avasarala J, Olson PA. Dosing schedules for ofatumumab in multiple sclerosis: overegging the pudding. Mult Scler Relat Disord. 2021;56(September): 103250.","journal-title":"Mult Scler Relat Disord."},{"issue":"6","key":"696_CR116","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357.","journal-title":"N Engl J Med"},{"issue":"10","key":"696_CR117","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1177\/13524585221079731","volume":"28","author":"SL Hauser","year":"2022","unstructured":"Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, et al. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Mult Scler J. 2022;28(10):1576\u201390.","journal-title":"Mult Scler J"},{"issue":"October","key":"696_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104246","volume":"68","author":"S El Mahdaoui","year":"2022","unstructured":"El Mahdaoui S, Romme Christensen J, Magyari M, Wandall-Holm MF, Sellebjerg F. Intravenous ofatumumab treatment of multiple sclerosis and related disorders: an observational study. Mult Scler Relat Disord. 2022;68(October): 104246.","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"696_CR119","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","volume":"111","author":"B Coiffier","year":"2008","unstructured":"Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, Van Oers MHJ, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1\u20132 study. Blood. 2008;111(3):1094\u2013100.","journal-title":"Blood"},{"issue":"5","key":"696_CR120","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/leu.2011.329","volume":"26","author":"DE Spaner","year":"2012","unstructured":"Spaner DE. Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia. Leukemia. 2012;26(5):1144\u20135.","journal-title":"Leukemia"},{"issue":"August","key":"696_CR121","first-page":"1","volume":"13","author":"S Faissner","year":"2022","unstructured":"Faissner S, Heitmann N, Plaza-Sirvent C, Trendelenburg P, Ceylan U, Motte J, et al. Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination. Front Immunol. 2022;13(August):1\u201313.","journal-title":"Front Immunol"},{"key":"696_CR122","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/vaccines11050978","volume":"11","author":"T Ziemssen","year":"2023","unstructured":"Ziemssen T, Schlegel E, Groth M, Ettle B, Bopp T. Results on SARS-CoV-2 mRNA vaccine booster from an open-label multicenter study in ofatumumab-treated participants with relapsing multiple sclerosis. Vaccines. 2023;11:978.","journal-title":"Vaccines"},{"issue":"21","key":"696_CR123","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1182\/blood.V124.21.4684.4684","volume":"124","author":"A \u00d6sterborg","year":"2014","unstructured":"\u00d6sterborg A, Udvardy M, Zaritskey A, Andersson PO, Grosicki S, Mazur G, et al. Ofatumumab (OFA) vs. physician\u2019s choice (PC) of therapy in patients (pts) with bulky fludarabine refractory (BFR) chronic lymphocytic leukaemia (CLL): results of the phase III study OMB114242. Blood. 2014;124(21):4684\u20134684.","journal-title":"Blood"},{"issue":"8","key":"696_CR124","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704\u201314.","journal-title":"N Engl J Med"},{"issue":"5","key":"696_CR125","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40265-023-01854-z","volume":"83","author":"A Lee","year":"2023","unstructured":"Lee A. Ublituximab: first approval. Drugs. 2023;83(5):455\u20139.","journal-title":"Drugs"},{"issue":"3","key":"696_CR126","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/1352458520918375","volume":"27","author":"E Fox","year":"2021","unstructured":"Fox E, Lovett-Racke AE, Gormley M, Liu Y, Petracca M, Cocozza S, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler J. 2021;27(3):420\u20139.","journal-title":"Mult Scler J"},{"issue":"April","key":"696_CR127","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jneuroim.2019.04.017","volume":"332","author":"AE Lovett-Racke","year":"2019","unstructured":"Lovett-Racke AE, Gormley M, Liu Y, Yang Y, Graham C, Wray S, et al. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. J Neuroimmunol. 2019;332(April):187\u201397.","journal-title":"J Neuroimmunol"},{"key":"696_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577676","volume":"359","author":"AE Lovett-Racke","year":"2021","unstructured":"Lovett-Racke AE, Yang Y, Liu Y, Gormley M, Kraus E, Graham C, et al. B cell depletion changes the immune cell profile in multiple sclerosis patients: one-year report. J Neuroimmunol. 2021;359: 577676. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577676.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"696_CR129","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"696_CR130","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101\u201310.","journal-title":"N Engl J Med"},{"issue":"2","key":"696_CR131","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","volume":"118","author":"G Niederfellner","year":"2011","unstructured":"Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies. Blood. 2011;118(2):358\u201367.","journal-title":"Blood"},{"issue":"3","key":"696_CR132","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1517\/14712598.2012.657622","volume":"12","author":"C Owen","year":"2012","unstructured":"Owen C, Stewart DA. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther. 2012;12(3):343\u201351.","journal-title":"Expert Opin Biol Ther"},{"issue":"22","key":"696_CR133","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S, P\u00fcntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393\u2013402.","journal-title":"Blood"},{"issue":"7","key":"696_CR134","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","volume":"56","author":"V Reddy","year":"2017","unstructured":"Reddy V, Klein C, Isenberg DA, Glennie MJ, Cambridge G, Cragg MS, et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (United Kingdom). 2017;56(7):1227\u201337.","journal-title":"Rheumatology (United Kingdom)."},{"issue":"23","key":"696_CR135","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, D\u00fcrig J, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36(23):2395\u2013404.","journal-title":"J Clin Oncol"},{"issue":"31","key":"696_CR136","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trneny M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large b-cell lymphoma. J Clin Oncol. 2017;35(31):3529\u201337.","journal-title":"J Clin Oncol"},{"issue":"7","key":"696_CR137","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","volume":"122","author":"J Radford","year":"2013","unstructured":"Radford J, Davies A, Cartron G, Morschhauser F, Salles G, Marcus R, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122(7):1137\u201343.","journal-title":"Blood"},{"issue":"14","key":"696_CR138","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood-2014-07-586610","volume":"124","author":"G Cartron","year":"2014","unstructured":"Cartron G, De Guibert S, Dilhuydy MS, Morschhauser F, Leblond V, Dupuis J, et al. Obinutuzumab (GA101) in relapsed\/refractory chronic lymphocytic leukemia: final data from the phase 1\/2 GAUGUIN study. Blood. 2014;124(14):2196\u2013202.","journal-title":"Blood"},{"issue":"23","key":"696_CR139","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","volume":"31","author":"GA Salles","year":"2013","unstructured":"Salles GA, Morschhauser F, Solal-C\u00e9ligny P, Thieblemont C, Lamy T, Tilly H, et al. Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non-hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2920\u20136.","journal-title":"J Clin Oncol"},{"key":"696_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286418761697","volume":"11","author":"TG Forsthuber","year":"2018","unstructured":"Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, St\u00fcve O. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord. 2018;11:1\u201313.","journal-title":"Ther Adv Neurol Disord"},{"issue":"18","key":"696_CR141","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1056\/NEJMoa051568","volume":"354","author":"MC van Zelm","year":"2006","unstructured":"van Zelm MC, Reisli I, van der Burg M, Casta\u00f1o D, van Noesel CJM, van Tol MJD, et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006;354(18):1901\u201312.","journal-title":"N Engl J Med"},{"issue":"1","key":"696_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):1\u20137.","journal-title":"Exp Hematol Oncol"},{"issue":"13","key":"696_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.166137","volume":"8","author":"JS Boyles","year":"2023","unstructured":"Boyles JS, Sadowski D, Potter S, Vukojicic A, Parker J, Chang WY, et al. A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases. JCI Insight. 2023;8(13):1\u201320.","journal-title":"JCI Insight."},{"key":"696_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104321","volume":"86","author":"JL Bennett","year":"2022","unstructured":"Bennett JL, Aktas O, Rees WA, Smith MA, Gunsior M, Yan L, et al. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: an exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2\/3 trial. EBioMedicine. 2022;86: 104321.","journal-title":"EBioMedicine"},{"issue":"October","key":"696_CR145","first-page":"1","volume":"14","author":"K Ilieva","year":"2023","unstructured":"Ilieva K, Eberl M, Jaehrling J, Blair D, Patra-Kneuer M, Boxhammer R, et al. Preclinical study of CD19 detection methods post tafasitamab treatment. Front Immunol. 2023;14(October):1\u20137.","journal-title":"Front Immunol"},{"issue":"1","key":"696_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hem3.39","volume":"8","author":"L Proost","year":"2024","unstructured":"Proost L, Lambrecht S, Hofmans M, De Vriendt C, Speeckaert M, Bonroy C, et al. Flow cytometry interference in patients treated with tafasitamab: unraveling the diagnostic maze. Hemasphere. 2024;8(1):1\u20135.","journal-title":"Hemasphere."},{"issue":"February","key":"696_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103794","volume":"62","author":"V Jovicevic","year":"2022","unstructured":"Jovicevic V, Ivanovic J, Momcilovic N, Andabaka M, Tamas O, Veselinovic N, et al. Humoral response to SARS-CoV-2 infection and vaccines against COVID-19 in patients with neuromyelitis optica spectrum disorders: impact of immunosuppressive treatment. Mult Scler Relat Disord. 2022;62(February): 103794.","journal-title":"Mult Scler Relat Disord."},{"issue":"16","key":"696_CR148","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1182\/blood.2023020637","volume":"142","author":"D Belada","year":"2023","unstructured":"Belada D, Kopeckova K, Bergua Burgues JM, Stevens D, Andr\u00e9 M, Persona EP, et al. Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b first-MIND study. Blood. 2023;142(16):1348\u201358.","journal-title":"Blood"},{"issue":"10206","key":"696_CR149","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. The Lancet. 2019;394(10206):1352\u201363.","journal-title":"The Lancet"},{"issue":"12","key":"696_CR150","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton JE. Inebilizumab: first approval. Drugs. 2020;80(12):1259\u201364.","journal-title":"Drugs"},{"issue":"6","key":"696_CR151","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/13524585211047223","volume":"28","author":"M Rensel","year":"2022","unstructured":"Rensel M, Zabeti A, Mealy MA, Cimbora D, She D, Drappa J, et al. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for \u2a7e4 years in the N-MOmentum trial. Mult Scler. 2022;28(6):925\u201332.","journal-title":"Mult Scler"},{"issue":"6","key":"696_CR152","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s12185-019-02635-9","volume":"109","author":"K Ohmachi","year":"2019","unstructured":"Ohmachi K, Ogura M, Suehiro Y, Ando K, Uchida T, Choi I, et al. A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma. Int J Hematol. 2019;109(6):657\u201364.","journal-title":"Int J Hematol"},{"issue":"7","key":"696_CR153","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.4049\/jimmunol.1003412","volume":"186","author":"HM Horton","year":"2011","unstructured":"Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IWL, et al. Antibody-mediated coengagement of Fc\u03b3RIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011;186(7):4223\u201333.","journal-title":"J Immunol"},{"issue":"15","key":"696_CR154","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1016\/j.molimm.2008.06.027","volume":"45","author":"SY Chu","year":"2008","unstructured":"Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, et al. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and Fc\u03b3RIIb with Fc-engineered antibodies. Mol Immunol. 2008;45(15):3926\u201333.","journal-title":"Mol Immunol"},{"issue":"2","key":"696_CR155","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40259-019-00400-2","volume":"34","author":"Q Zhao","year":"2020","unstructured":"Zhao Q. Bispecific antibodies for autoimmune and inflammatory diseases: clinical progress to date. BioDrugs. 2020;34(2):111\u20139.","journal-title":"BioDrugs"},{"issue":"8","key":"696_CR156","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1016\/S2665-9913(23)00157-1","volume":"5","author":"CA Perugino","year":"2023","unstructured":"Perugino CA, Wallace ZS, Zack DJ, Quinn SM, Poma A, Fernandes AD, et al. Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial. Lancet Rheumatol. 2023;5(8):e442\u201350.","journal-title":"Lancet Rheumatol."},{"issue":"12","key":"696_CR157","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/art.42652","volume":"75","author":"JT Merrill","year":"2023","unstructured":"Merrill JT, Guthridge J, Smith M, June J, Koumpouras F, Machua W, et al. Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co\u2010expression patterns: a double\u2010blind, randomized, placebo\u2010controlled, phase 2 trial. Arthritis Rheumatol. 2023;75(12):2185\u201394.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"696_CR158","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41584-020-0500-7","volume":"16","author":"CA Perugino","year":"2020","unstructured":"Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol. 2020;16(12):702\u201314.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"696_CR159","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci L, Hagen M, Rothe T, Raimondo MG, Fagni F, Tur C, et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med. 2024;30(6):1593\u2013601.","journal-title":"Nat Med"},{"issue":"7","key":"696_CR160","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00262-003-0496-2","volume":"53","author":"M Gruen","year":"2004","unstructured":"Gruen M, Bommert K, Bargou RC. T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol Immunother. 2004;53(7):625\u201332.","journal-title":"Cancer Immunol Immunother"},{"issue":"26","key":"696_CR161","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226\u201333.","journal-title":"Blood"},{"issue":"6","key":"696_CR162","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci L, Hagen M, Rothe T, Raimondo MG, Fagni F, Tur C, et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med. 2024;30(6):1593\u2013601. https:\/\/doi.org\/10.1038\/s41591-024-02964-1.","journal-title":"Nat Med"},{"issue":"9","key":"696_CR163","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/bcj.2014.64","volume":"4","author":"G Zugmaier","year":"2014","unstructured":"Zugmaier G, Topp MS, Alekar S, Viardot A, Horst HA, Neumann S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4(9):4\u20137.","journal-title":"Blood Cancer J"},{"issue":"23","key":"696_CR164","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255\u201373.","journal-title":"N Engl J Med"},{"issue":"9","key":"696_CR165","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","volume":"61","author":"L Coyle","year":"2020","unstructured":"Coyle L, Morley NJ, Rambaldi A, Mason KD, Verhoef G, Furness CL, et al. Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2020;61(9):2103\u201312.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"696_CR166","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00277-019-03854-0","volume":"99","author":"A Apel","year":"2020","unstructured":"Apel A, Ofran Y, Wolach O, Shimony S, Ram R, Levi I, et al. Safety and efficacy of blinatumomab: a real world data. Ann Hematol. 2020;99(4):835\u20138.","journal-title":"Ann Hematol"},{"issue":"7","key":"696_CR167","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978\u201388.","journal-title":"Lancet Oncol"},{"issue":"9","key":"696_CR168","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.3324\/haematol.2020.275958","volume":"106","author":"J Duell","year":"2021","unstructured":"Duell J, Maddocks KJ, Gonz\u00e1lez-Barca E, Jurczak W, Liberati AM, de Vos S, et al. Long-term L-MIND study outcomes of tafasitamab from the(MOR208) phase II plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021;106(9):2417\u201326.","journal-title":"Haematologica"},{"key":"696_CR169","doi-asserted-by":"crossref","unstructured":"Belada D, Kopeckova K, Bergua Burgues JM, Stevens DA, Nowakowski GS, Waldron-Lynch M, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) in First-MIND: a phase Ib, open-label, randomized study of tafasitamab (tafa) \u00b1 lenalidomide (LEN) in addition to R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2022;40(16_suppl):e19553.","DOI":"10.1200\/JCO.2022.40.16_suppl.e19553"},{"issue":"10","key":"696_CR170","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A. Loncastuximab tesirine: first approval. Drugs. 2021;81(10):1229\u201333.","journal-title":"Drugs"},{"issue":"6","key":"696_CR171","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790\u2013800.","journal-title":"Lancet Oncol"},{"issue":"5","key":"696_CR172","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00228-021-03253-3","volume":"78","author":"B Xu","year":"2022","unstructured":"Xu B. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma. Eur J Clin Pharmacol. 2022;78(5):707\u201319.","journal-title":"Eur J Clin Pharmacol"},{"issue":"19","key":"696_CR173","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood.2020007512","volume":"137","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O\u2019Connor OA, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634\u201345.","journal-title":"Blood"},{"issue":"5","key":"696_CR174","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","volume":"18","author":"C Bossen","year":"2006","unstructured":"Bossen C, Schneider P. BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol. 2006;18(5):263\u201375.","journal-title":"Semin Immunol"},{"issue":"OCT","key":"696_CR175","first-page":"1","volume":"9","author":"CR Smulski","year":"2018","unstructured":"Smulski CR, Eibel H. BAFF and BAFF-receptor in B cell selection and survival. Front Immunol. 2018;9(OCT):1\u201310.","journal-title":"Front Immunol"},{"issue":"3","key":"696_CR176","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.coi.2005.04.005","volume":"17","author":"P Schneider","year":"2005","unstructured":"Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol. 2005;17(3):282\u20139.","journal-title":"Curr Opin Immunol"},{"issue":"17","key":"696_CR177","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","volume":"376","author":"M Steri","year":"2017","unstructured":"Steri M, Orr\u00f9 V, Idda ML, Pitzalis M, Pala M, Zara I, et al. Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med. 2017;376(17):1615\u201326.","journal-title":"N Engl J Med"},{"issue":"8","key":"696_CR178","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1084\/jem.20062567","volume":"204","author":"JR Groom","year":"2007","unstructured":"Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, Sweet MJ, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med. 2007;204(8):1959\u201371.","journal-title":"J Exp Med"},{"issue":"7","key":"696_CR179","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","volume":"9","author":"F MacKay","year":"2009","unstructured":"MacKay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491\u2013502.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"696_CR180","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2009","unstructured":"Elgueta R, Benson MJ, De Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152\u201372.","journal-title":"Immunol Rev"},{"issue":"7533","key":"696_CR181","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature13803","volume":"517","author":"D Liu","year":"2015","unstructured":"Liu D, Xu H, Shih C, Wan Z, Ma X, Ma W, et al. T-B-cell entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction. Nature. 2015;517(7533):214\u20138.","journal-title":"Nature"},{"issue":"3","key":"696_CR182","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s12026-023-09449-2","volume":"72","author":"Y Wu","year":"2023","unstructured":"Wu Y, Li Y, Wu T, Huang D, Wu J, Zhang W, et al. COVID-19 in systemic lupus erythematosus patients treated with belimumab: a retrospective clinical study. Immunol Res. 2023;72(3):418\u201329.","journal-title":"Immunol Res"},{"issue":"7","key":"696_CR183","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/annrheumdis-2021-221636","volume":"81","author":"MF Ugarte-Gil","year":"2022","unstructured":"Ugarte-Gil MF, Alarc\u00f3n GS, Izadi Z, Duarte-Garc\u00eda A, Re\u00e1tegui-Sokolova C, Clarke AE, et al. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 global rheumatology alliance. Ann Rheum Dis. 2022;81(7):970\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"696_CR184","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/15563316221142846","volume":"19","author":"J Zhang-Sun","year":"2023","unstructured":"Zhang-Sun J, Kirou RA, Kirou KA. Low peripheral B-cell counts in patients with systemic rheumatic diseases due to treatment with belimumab and\/or rituximab are associated with low antibody responses to primary COVID-19 vaccination. HSS J. 2023;19(2):180\u20136.","journal-title":"HSS J"},{"issue":"4","key":"696_CR185","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/09612033241230736","volume":"33","author":"PC Liu","year":"2024","unstructured":"Liu PC, Zhang M, Li JB, Peng YL, Yu SJ, Wu R. Factors affecting different COVID-19 outcomes in patients with systemic lupus erythematosus during the second pandemic wave of COVID-19 in China. Lupus. 2024;33(4):357\u201364.","journal-title":"Lupus"},{"issue":"12","key":"696_CR186","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzov\u00e1 D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918\u201330.","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"696_CR187","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. The Lancet. 2011;377(9767):721\u201331.","journal-title":"The Lancet"},{"issue":"9","key":"696_CR188","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/art.24699","volume":"61","author":"DJ Wallace","year":"2009","unstructured":"Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2009;61(9):1168\u201378.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"1","key":"696_CR189","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40744-020-00193-9","volume":"7","author":"J Zhang","year":"2020","unstructured":"Zhang J, Wan W, Miao L, Wu J, Dong J, Shen Y, et al. Pharmacokinetics, pharmacodynamics and safety of belimumab in chinese patients with systemic lupus erythematosus: a phase I, open-label study. Rheumatol Ther. 2020;7(1):191\u2013200.","journal-title":"Rheumatol Ther."},{"issue":"1","key":"696_CR190","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/art.27189","volume":"62","author":"AM Jacobi","year":"2010","unstructured":"Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201\u201310.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"696_CR191","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.3899\/jrheum.111587","volume":"39","author":"WW Chatham","year":"2012","unstructured":"Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol. 2012;39(8):1632\u201340.","journal-title":"J Rheumatol"},{"issue":"14","key":"696_CR192","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1177\/0961203317703495","volume":"26","author":"W Chatham","year":"2017","unstructured":"Chatham W, Chadha A, Fettiplace J, Kleoudis C, Bass D, Roth D, et al. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. Lupus. 2017;26(14):1483\u201390.","journal-title":"Lupus"},{"issue":"June","key":"696_CR193","first-page":"1","volume":"14","author":"J Cai","year":"2023","unstructured":"Cai J, Gao D, Liu D, Liu Z. Telitacicept for autoimmune nephropathy. Front Immunol. 2023;14(June):1\u20139.","journal-title":"Front Immunol"},{"issue":"3","key":"696_CR194","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","volume":"63","author":"D Xu","year":"2024","unstructured":"Xu D, Fang J, Zhang S, Huang C, Huang C, Qin L, et al. Efficacy and safety of telitacicept in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology. 2024;63(3):698\u2013705.","journal-title":"Rheumatology"},{"issue":"1","key":"696_CR195","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","volume":"32","author":"R Chen","year":"2023","unstructured":"Chen R, Fu R, Lin Z, Huang C, Huang W. The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus. 2023;32(1):94\u2013100.","journal-title":"Lupus"},{"issue":"3","key":"696_CR196","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2023","unstructured":"Lv J, Liu L, Hao C, Li G, Fu P, Xing G, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep. 2023;8(3):499\u2013506.","journal-title":"Kidney Int Rep."},{"key":"696_CR197","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jcph.686","volume":"41","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Chen X, Hou Y, Jiang J, Zhong W, Yao X, et al. Pharmacokinetics, pharmacodynamics, safety, and clinical activity of multiple doses of RCT-18 in Chinese patients with systemic lupus erythematosus. J Clin Pharmacol. 2016;41:948\u201359.","journal-title":"J Clin Pharmacol"},{"key":"696_CR198","first-page":"4546","volume":"74","author":"D Wu","year":"2022","unstructured":"Wu D, Li J, Xu D, Wang L, Fang J, Ross D, et al. Telitacicept, a human recombinant fusion protein targeting B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL), in systemic lupus erythematosus (SLE): results of a phase 3 study. Arthritis Rheumatol. 2022;74:4546\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"696_CR199","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"8","key":"696_CR200","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021;5(8):2196\u2013215.","journal-title":"Blood Adv"},{"key":"696_CR201","doi-asserted-by":"crossref","unstructured":"Guo Y, Quijano\u00a0Card\u00e9 NA, Kang L, Verona R, Banerjee A, Kobos R, et al. Teclistamab: mechanism of action, clinical, and translational science. Vol. 17, Clinical and Translational Science. Wiley; 2024.","DOI":"10.1111\/cts.13717"},{"issue":"Supplement 1","key":"696_CR202","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2022-162709","volume":"140","author":"D Cortes-Selva","year":"2022","unstructured":"Cortes-Selva D, Casneuf T, Vishwamitra D, Stein S, Perova T, Skerget S, et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): correlative analyses from MajesTEC-1. Blood. 2022;140(Supplement 1):241\u20133.","journal-title":"Blood"},{"issue":"1","key":"696_CR203","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","volume":"8","author":"KA Frerichs","year":"2024","unstructured":"Frerichs KA, Verkleij CPM, Mateos MV, Martin TG, Rodriguez C, Nooka A, et al. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Adv. 2024;8(1):194\u2013206.","journal-title":"Blood Adv"},{"issue":"10301","key":"696_CR204","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665\u201374.","journal-title":"Lancet"},{"issue":"25","key":"696_CR205","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","volume":"380","author":"X Montalban","year":"2019","unstructured":"Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med. 2019;380(25):2406\u201317.","journal-title":"N Engl J Med"},{"issue":"6","key":"696_CR206","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","volume":"150","author":"M Maurer","year":"2022","unstructured":"Maurer M, Berger W, Gim\u00e9nez-Arnau A, Hayama K, Jain V, Reich A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;150(6):1498-1506.e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"696_CR207","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nchembio.481","volume":"7","author":"JA Di Paolo","year":"2011","unstructured":"Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol. 2011;7(1):41\u201350.","journal-title":"Nat Chem Biol"},{"key":"696_CR208","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ijid.2021.02.056","volume":"105","author":"S Maynard","year":"2021","unstructured":"Maynard S, Ros-Soto J, Chaidos A, Innes A, Paleja K, Mirvis E, et al. The role of ibrutinib in COVID-19 hyperinflammation: a case report. Int J Infect Dis. 2021;105:274\u20136.","journal-title":"Int J Infect Dis"},{"issue":"48","key":"696_CR209","doi-asserted-by":"publisher","first-page":"eabd0110","DOI":"10.1126\/sciimmunol.abd0110","volume":"5","author":"M Roschewski","year":"2020","unstructured":"Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5(48):eabd0110.","journal-title":"Sci Immunol."},{"issue":"13","key":"696_CR210","doi-asserted-by":"publisher","first-page":"7071","DOI":"10.3390\/ijms22137071","volume":"22","author":"S Kaliamurthi","year":"2021","unstructured":"Kaliamurthi S, Selvaraj G, Selvaraj C, Singh SK, Wei DQ, Peslherbe GH. Structure-based virtual screening reveals ibrutinib and zanubrutinib as potential repurposed drugs against covid-19. Int J Mol Sci. 2021;22(13):7071.","journal-title":"Int J Mol Sci"},{"key":"696_CR211","unstructured":"Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19 [Internet]. [cited 2024 May 10]. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/update-on-calavi-phase-ii-trials-for-calquence-in-patients-hospitalised-with-respiratory-symptoms-of-covid-19.html#."},{"key":"696_CR212","unstructured":"Study Results | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | ClinicalTrials.gov [Internet]. [cited 2024 May 10]. https:\/\/clinicaltrials.gov\/study\/NCT04382586?term=Zanubrutinib&cond=Covid19&city=&rank=1&tab=results#outcome-measures."},{"issue":"1","key":"696_CR213","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):1\u201323.","journal-title":"Mol Cancer"},{"issue":"2","key":"696_CR214","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000509286","volume":"144","author":"CN Grimont","year":"2021","unstructured":"Grimont CN, Castillo Almeida NE, Gertz MA. Current and emerging treatments for Waldenstr\u00f6m macroglobulinemia. Acta Haematol. 2021;144(2):146\u201357.","journal-title":"Acta Haematol"},{"issue":"18","key":"696_CR215","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038\u201350.","journal-title":"Blood"},{"issue":"5","key":"696_CR216","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1177\/1078155220915956","volume":"26","author":"KS Hanna","year":"2020","unstructured":"Hanna KS, Campbell M, Husak A, Sturm S. The role of Bruton\u2019s tyrosine kinase inhibitors in the management of mantle cell lymphoma. J Oncol Pharm Pract. 2020;26(5):1190\u20139.","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"696_CR217","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/s10637-014-0141-2","volume":"32","author":"N Grabinski","year":"2014","unstructured":"Grabinski N, Ewald F. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Invest New Drugs. 2014;32(6):1096\u2013104.","journal-title":"Invest New Drugs"},{"issue":"15","key":"696_CR218","doi-asserted-by":"publisher","first-page":"13255","DOI":"10.18632\/oncotarget.3658","volume":"6","author":"MA Zucha","year":"2015","unstructured":"Zucha MA, Wu ATH, Lee WH, Wang LS, Lin WW, Yuan CC, et al. Bruton\u2019s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Oncotarget. 2015;6(15):13255\u201368.","journal-title":"Oncotarget"},{"issue":"7","key":"696_CR219","first-page":"3003","volume":"8","author":"JD Wang","year":"2016","unstructured":"Wang JD, Chen XY, Ji KW, Tao F. Targeting Btk with ibrutinib inhibit gastric carcinoma cells growth. Am J Transl Res. 2016;8(7):3003\u201312.","journal-title":"Am J Transl Res."},{"issue":"9","key":"696_CR220","doi-asserted-by":"publisher","first-page":"dju204","DOI":"10.1093\/jnci\/dju204","volume":"106","author":"W Gao","year":"2014","unstructured":"Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, et al. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014;106(9):dju204.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"696_CR221","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1016\/S2352-3026(15)00046-0","volume":"2","author":"SA Rushworth","year":"2015","unstructured":"Rushworth SA, Pillinger G, Abdul-Aziz A, Piddock R, Shafat MS, Murray MY, et al. Activity of Bruton\u2019s tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells. Lancet Haematol. 2015;2(5):e204\u201311.","journal-title":"Lancet Haematol."},{"issue":"9","key":"696_CR222","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1182\/blood-2016-06-722900","volume":"129","author":"E Kim","year":"2017","unstructured":"Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, et al. Ibrutinib inhibits pre-BCR(+) B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood. 2017;129(9):1155\u201365.","journal-title":"Blood"},{"issue":"4","key":"696_CR223","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cbpa.2010.06.168","volume":"14","author":"J Singh","year":"2010","unstructured":"Singh J, Petter RC, Kluge AF. Targeted covalent drugs of the kinase family. Curr Opin Chem Biol. 2010;14(4):475\u201380.","journal-title":"Curr Opin Chem Biol"},{"issue":"October","key":"696_CR224","first-page":"1","volume":"12","author":"M Allouchery","year":"2021","unstructured":"Allouchery M, Tomowiak C, Lombard T, P\u00e9rault-Pochat MC, Salvo F. Safety profile of ibrutinib: an analysis of the WHO pharmacovigilance database. Front Pharmacol. 2021;12(October):1\u201311.","journal-title":"Front Pharmacol"},{"issue":"23","key":"696_CR225","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SEM Herman","year":"2011","unstructured":"Herman SEM, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287\u201396.","journal-title":"Blood"},{"key":"696_CR226","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106520","volume":"102","author":"IG Solman","year":"2021","unstructured":"Solman IG, Blum LK, Burger JA, Kipps TJ, Dean JP, James DF, et al. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leuk Res. 2021;102: 106520. https:\/\/doi.org\/10.1016\/j.leukres.2021.106520.","journal-title":"Leuk Res"},{"issue":"4","key":"696_CR227","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1080\/10428194.2018.1512710","volume":"60","author":"JC Barrientos","year":"2019","unstructured":"Barrientos JC, Burger JA, Byrd JC, Hillmen P, Zhou C, Ninomoto J, et al. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019;60(4):1000\u20135.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"696_CR228","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","volume":"123","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810\u20137.","journal-title":"Blood"},{"issue":"3","key":"696_CR229","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s12032-007-9037-8","volume":"25","author":"DT Alexandrescu","year":"2008","unstructured":"Alexandrescu DT, Wiernik PH. Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia. Med Oncol. 2008;25(3):309\u201314.","journal-title":"Med Oncol"},{"issue":"19","key":"696_CR230","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","volume":"126","author":"C Sun","year":"2015","unstructured":"Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SEM, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213\u20139.","journal-title":"Blood"},{"issue":"1","key":"696_CR231","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32\u201342.","journal-title":"N Engl J Med"},{"issue":"10","key":"696_CR232","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1080\/10428194.2020.1772477","volume":"61","author":"C Pleyer","year":"2020","unstructured":"Pleyer C, Sun C, Desai S, Ahn IE, Tian X, Nierman P, et al. Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors. Leuk Lymphoma. 2020;61(10):2375\u201382.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"696_CR233","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1001\/jamaoncol.2016.2437","volume":"2","author":"C Sun","year":"2016","unstructured":"Sun C, Gao J, Couzens L, Tian X, Farooqui MZ, Eichelberger MC, et al. Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib. JAMA Oncol. 2016;2(12):1656.","journal-title":"JAMA Oncol"},{"issue":"6","key":"696_CR234","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1182\/bloodadvances.2021006574","volume":"6","author":"C Pleyer","year":"2022","unstructured":"Pleyer C, Laing KJ, Ali MA, McClurkan CL, Soto S, Ahn IE, et al. BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL. Blood Adv. 2022;6(6):1732\u201340.","journal-title":"Blood Adv"},{"issue":"2","key":"696_CR235","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.htct.2021.07.002","volume":"44","author":"MAU Din","year":"2022","unstructured":"Din MAU, Liaqat H, Anwer F. Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review. Hematol Transfus Cell Ther. 2022;44(2):293\u20136.","journal-title":"Hematol Transfus Cell Ther."},{"issue":"5","key":"696_CR236","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/bjh.14855","volume":"182","author":"B Andrick","year":"2018","unstructured":"Andrick B, Alwhaibi A, DeRemer DL, Quershi S, Khan R, Bryan LJ, et al. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. Br J Haematol. 2018;182(5):712\u20134.","journal-title":"Br J Haematol"},{"issue":"23","key":"696_CR237","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood.2021011568","volume":"137","author":"Y Herishanu","year":"2021","unstructured":"Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165\u201373.","journal-title":"Blood"},{"issue":"6","key":"696_CR238","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/s41375-020-01074-4","volume":"35","author":"CS Zent","year":"2021","unstructured":"Zent CS, Brady MT, Delage C, Strawderman M, Laniewski N, Contant PN, et al. Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma. Leukemia. 2021;35(6):1788\u201391.","journal-title":"Leukemia"},{"issue":"15 suppl","key":"696_CR239","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/jco.2010.28.15_suppl.8012","volume":"28","author":"R Advani","year":"2010","unstructured":"Advani R, Sharman JP, Smith SM, Pollyea DA, Boyd TE, Grant BW, et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J Clin Oncol. 2010;28(15 suppl):8012.","journal-title":"J Clin Oncol"},{"key":"696_CR240","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106520","volume":"102","author":"IG Solman","year":"2021","unstructured":"Solman IG, Blum LK, Burger JA, Kipps TJ, Dean JP, James DF, et al. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leuk Res. 2021;102: 106520.","journal-title":"Leuk Res"},{"issue":"15","key":"696_CR241","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539\u201349.","journal-title":"Blood"},{"key":"696_CR242","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106432","volume":"97","author":"IG Solman","year":"2020","unstructured":"Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, et al. Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia. Leuk Res. 2020;97: 106432.","journal-title":"Leuk Res"},{"issue":"1","key":"696_CR243","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/cid\/cix687","volume":"66","author":"G Chamilos","year":"2018","unstructured":"Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis. 2018;66(1):140\u20138.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"696_CR244","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103010","volume":"152","author":"K Hou","year":"2020","unstructured":"Hou K, Yu Z, Jia Y, Fang H, Shao S, Huang L, et al. Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: a single-arm meta-analysis. Crit Rev Oncol Hematol. 2020;152(11): 103010.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"696_CR245","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40199-022-00444-w","volume":"30","author":"M Roufarshbaf","year":"2022","unstructured":"Roufarshbaf M, Javeri M, Akbari V, Matin PH, Farrokhi P, Sadeghi E, et al. Efficacy and safety of ibrutinib in mantle cell lymphoma: a systematic review and meta-analysis. DARU J Pharm Sci. 2022;30(2):367\u201378.","journal-title":"DARU J Pharm Sci."},{"key":"696_CR246","first-page":"3460","volume":"130","author":"B Tillman","year":"2017","unstructured":"Tillman B, Pauff JM, Satyanarayana G, Talbott MS, Warner J. Systematic review of infectious events in prospective trials of ibrutinib. Blood. 2017;130:3460.","journal-title":"Blood"},{"issue":"17","key":"696_CR247","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","volume":"131","author":"D Ghez","year":"2018","unstructured":"Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955\u20139.","journal-title":"Blood"},{"issue":"15","key":"696_CR248","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1182\/blood-2016-06-722991","volume":"128","author":"IE Ahn","year":"2016","unstructured":"Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128(15):1940\u20133.","journal-title":"Blood"},{"issue":"12","key":"696_CR249","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","volume":"123","author":"HE Kohrt","year":"2014","unstructured":"Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SEM, Butchar JP, Cheney C, et al. Ibrutinib antagonizes rituximab-dependent NK cell\u2013mediated cytotoxicity. Blood. 2014;123(12):1957\u201360.","journal-title":"Blood"},{"issue":"2","key":"696_CR250","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1097\/DAD.0000000000000980","volume":"40","author":"J Stewart","year":"2018","unstructured":"Stewart J, Bayers S, Vandergriff T. Self-limiting ibrutinib-induced neutrophilic panniculitis. Am J Dermatopathol. 2018;40(2):e28\u20139.","journal-title":"Am J Dermatopathol"},{"issue":"5","key":"696_CR251","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1001\/jamaoncol.2015.0457","volume":"1","author":"SK Fabbro","year":"2015","unstructured":"Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA. Panniculitis in patients undergoing treatment with the bruton tyrosine kinase inhibitor ibrutinib for lymphoid leukemias. JAMA Oncol. 2015;1(5):684\u20136.","journal-title":"JAMA Oncol"},{"issue":"1","key":"696_CR252","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40265-017-0852-8","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A, Dhillon S. Acalabrutinib: first global approval. Drugs. 2018;78(1):139\u201345.","journal-title":"Drugs"},{"issue":"1","key":"696_CR253","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Zanubrutinib: first approval. Drugs. 2020;80(1):91\u20137.","journal-title":"Drugs"},{"issue":"3","key":"696_CR254","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/sji.12333","volume":"82","author":"A Bergl\u00f6f","year":"2015","unstructured":"Bergl\u00f6f A, Hamasy A, Meinke S, Palma M, Krstic A, M\u00e5nsson R, et al. Targets for ibrutinib beyond B cell malignancies. Scand J Immunol. 2015;82(3):208\u201317.","journal-title":"Scand J Immunol"},{"issue":"May","key":"696_CR255","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.668162","volume":"11","author":"HA Abbas","year":"2021","unstructured":"Abbas HA, Wierda WG. Acalabrutinib: a selective bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies. Front Oncol. 2021;11(May): 668162.","journal-title":"Front Oncol"},{"issue":"4","key":"696_CR256","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/leu.2017.321","volume":"32","author":"VK Patel","year":"2018","unstructured":"Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, et al. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018;32(4):920\u201330.","journal-title":"Leukemia"},{"issue":"10","key":"696_CR257","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/17474086.2020.1817735","volume":"13","author":"PR Geethakumari","year":"2020","unstructured":"Geethakumari PR, Awan F. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. Expert Rev Hematol. 2020;13(10):1039\u201346.","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"696_CR258","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851\u20139.","journal-title":"Blood"},{"issue":"24","key":"696_CR259","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1182\/blood.2020009617","volume":"137","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Woyach JA, Furman RR, Martin P, O\u2019Brien S, Brown JR, et al. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021;137(24):3327\u201338.","journal-title":"Blood"},{"issue":"21","key":"696_CR260","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.2021014162","volume":"139","author":"Y Song","year":"2022","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139(21):3148\u201358.","journal-title":"Blood"},{"issue":"4","key":"696_CR261","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323\u201332.","journal-title":"N Engl J Med"},{"issue":"14","key":"696_CR262","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","volume":"23","author":"V Patel","year":"2017","unstructured":"Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, et al. Comparison of acalabrutinib, a selective bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res. 2017;23(14):3734\u201343.","journal-title":"Clin Cancer Res"},{"issue":"August","key":"696_CR263","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.727531","volume":"9","author":"S Zhu","year":"2021","unstructured":"Zhu S, Gokhale S, Jung J, Spirollari E, Tsai J, Arceo J, et al. Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets\u2014beyond B lymphocytes. Front Cell Dev Biol. 2021;9(August): 727531.","journal-title":"Front Cell Dev Biol."},{"issue":"Supplement_1","key":"696_CR264","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1182\/blood-2019-128706","volume":"134","author":"RR Furman","year":"2019","unstructured":"Furman RR, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, et al. Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: 42-month follow-up of a phase 2 study. Blood. 2019;134(Supplement_1):3039\u20133039.","journal-title":"Blood"},{"issue":"26","key":"696_CR265","first-page":"3137","volume":"141","author":"PA Thompson","year":"2023","unstructured":"Thompson PA, Tam CS. Pirtobrutinib: a new hope for patients with BTK inhibitor\u2013refractory lymphoproliferative disorders. Blood. 2023;141(26):3137\u201342.","journal-title":"Blood"},{"issue":"1","key":"696_CR266","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389(1):33\u201344.","journal-title":"N Engl J Med"},{"issue":"6","key":"696_CR267","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Pirtobrutinib: first approval. Drugs. 2023;83(6):547\u201353.","journal-title":"Drugs"},{"issue":"1","key":"696_CR268","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/10781552231216886","volume":"30","author":"DD Davis","year":"2024","unstructured":"Davis DD, Ohana Z, Pham HM. Pirtobrutinib: a novel non-covalent BTK inhibitor for the treatment of adults with relapsed\/refractory mantle cell lymphoma. J Oncol Pharm Pract. 2024;30(1):182\u20138.","journal-title":"J Oncol Pharm Pract"},{"issue":"March","key":"696_CR269","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupi\u00f1\u00e1n","year":"2021","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9(March): 630942.","journal-title":"Front Cell Dev Biol."},{"issue":"6","key":"696_CR270","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.jaci.2021.12.790","volume":"149","author":"M Alligon","year":"2022","unstructured":"Alligon M, Mahlaoui N, Courteille V, Costes L, Afonso V, Randrianomenjanahary P, et al. An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: a study of a national retrospective cohort of 1375 patients over 10 years. J Allergy Clin Immunol. 2022;149(6):2116\u201325.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"696_CR271","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100513","volume":"14","author":"R Castagnoli","year":"2021","unstructured":"Castagnoli R, Lougaris V, Giardino G, Volpi S, Leonardi L, La Torre F, et al. Inborn errors of immunity with atopic phenotypes: a practical guide for allergists. World Allergy Organ J. 2021;14(2): 100513.","journal-title":"World Allergy Organ J"},{"issue":"SUPPL. 1","key":"696_CR272","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10875-008-9171-x","volume":"28","author":"AA Jesus","year":"2008","unstructured":"Jesus AA, Duarte AJS, Oliveira JB. Autoimmunity in hyper-IgM syndrome. J Clin Immunol. 2008;28(SUPPL. 1):62\u20136.","journal-title":"J Clin Immunol"},{"issue":"6","key":"696_CR273","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaci.2008.07.050","volume":"122","author":"SS De Ravin","year":"2008","unstructured":"De Ravin SS, Naumann N, Cowen EW, Friend J, Hilligoss D, Marquesen M, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol. 2008;122(6):1097\u2013103.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"696_CR274","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjh.12067","volume":"159","author":"D Oscier","year":"2012","unstructured":"Oscier D, Dearden C, Erem E, Fegan C, Follows G, Hillmen P, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159(5):541\u201364.","journal-title":"Br J Haematol"},{"issue":"8","key":"696_CR275","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366\u201383.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"696_CR276","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","volume":"149","author":"IM Otani","year":"2022","unstructured":"Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J Allergy Clin Immunol. 2022;149(5):1525\u201360. https:\/\/doi.org\/10.1016\/j.jaci.2022.01.025.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"696_CR277","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, D\u00f6rner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"696_CR278","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.autrev.2019.03.010","volume":"18","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka S, Mukhtyar C, Jayne D, Ala A, Bright P, Chinoy H, et al. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: systematic literature review. Autoimmun Rev. 2019;18(5):535\u201341.","journal-title":"Autoimmun Rev"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00696-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00696-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00696-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T22:00:57Z","timestamp":1737496857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00696-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":278,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["696"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00696-9","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"27 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SS is supported in part by the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre (BRC) (NIHR203331). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to participate\/publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MK, AA, and SS contributed to the conceptualisation of the publication. MK conducted the literature review and drafted the initial manuscript. AA and SS reviewed the initial and subsequent drafts, offering critical revisions. All authors\u2014MK, AA, and SS\u2014collaboratively wrote, reviewed, and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}